FDA Updates On Hyperinflation, Pancreatitis Risks Of Implantable Liquid-Filled Weight-Loss Balloons
Executive Summary
A letter from the US agency clarifies the risks of over-inflation, acute pancreatitis and death in patients who have been treated with liquid-filled intragastric balloons.
You may also be interested in...
Gastric Balloon Labeling Updated After Patient Deaths
US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.
With Roe v. Wade In Rearview, What’s Next For Women’s Health?
Manufacturers of devices and apps focused on reproductive health are still feeling out the import of a recent US Supreme Court decision overturning the federal right to abortion. Some attorneys say the ramifications may be vast.
For Second Time This Month, Medtronic Announces Class I FDA Recall Related To HeartWare System Component
Medtronic, Baxter and BD are all facing recalls, with Medtronic finding yet another issue with HeartWare HVAD systems. Separately, the FDA put a Baxter respiratory device recall into Class I, and BD announced a recall on intraosseous devices.